COMPANY OVERVIEW

CereSpir is targeting the emerging field of immuno-neurology via a novel mechanism for the treatment of Parkinson’s disease and other neurodegenerative diseases

---

LOCATION

New York, NY, USA

---

THERAPEUTIC AREAS

Neurodegenerative Disease

---

WEBSITE

https://www.cerespir.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Apr 16, 2020

CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier

Mar 26, 2019

CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR's Parkinson's Disease Development Program for Itanapraced

Dec 10, 2018

CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease 

Jan 7, 2015

CereSpir Incorporated Appoints Eric Karran, Ph.D., as Chairman of Its Scientific Advisory Board

Sep 30, 2014

CereSpir Incorporated Appoints Adrian N. Hobden, Ph.D., as Chairman of Its Board of Directors

For More Press Releases

---